

AMENDMENTS TO THE CLAIMS

In the Claims:

- 1-97. (Canceled)
98. (Currently Amended) A viral vector comprising a nucleic acid molecule of claim 117 ~~93~~.
99. (Currently Amended) A composition comprising the nucleic acid molecule of claim 117 ~~93~~, and a physiologically acceptable carrier or diluent.
100. (Previously Presented) The composition of claim 99, wherein the composition is a vaccine.
101. (Previously Presented) The composition of claim 99, further comprising an immunostimulatory substance.
102. (Previously Presented) The composition of claim 99, wherein the nucleic acid molecule is a DNA molecule.
103. -107. (Canceled)
108. (Currently Amended) A viral vector comprising a nucleic acid molecule of claim ~~403~~ 118.
109. (Currently Amended) A composition comprising the nucleic acid molecule of claim ~~403~~ 118, and a physiologically acceptable carrier or diluent.
110. (Previously Presented) The composition of claim 109, wherein the composition is a vaccine.
111. (Previously Presented) The composition of claim 109, further comprising an immunostimulatory substance.
112. (Previously Presented) The composition of claim 109, wherein the nucleic acid molecule is a DNA molecule.
113. (Currently Amended) A method of making a protein, the method comprising the steps of:
- (a) introducing into a cell an expression vector comprising a nucleic acid molecule, according to claims 117 or 118 ~~93 or 403~~;
 - (b) culturing the transfected cell; and
 - (c) purifying the expressed protein.
114. (Original) The method of claim 113, wherein the cell is a CHO cell.

115. (Original) The method of claim 113, wherein the cell is cultured in suspension, under serum-free conditions.
116. (Previously Presented) The method of claim 113, wherein the expressed protein is purified by a procedure comprising:
(a) anion exchange chromatography; and
(b) hydrophobic chromatography.
117. (Currently Amended) ~~The~~ An isolated nucleic acid molecule ~~of claim 93,~~
encoding a polypeptide comprising:
(a) an amino acid sequence of SEQ ID NO:3; and
(b) an amino acid sequence of SEQ ID NO:4;
wherein ~~(a) consists of SEQ ID NO:3 and (b) consists of SEQ ID NO:4~~ (a) and (b) are
joined by an amino acid linker sequence of no more than 50 amino acids; and
wherein said polypeptide does not comprise a HER-2/Neu transmembrane
domain.
118. (Currently Amended) ~~The~~ An isolated nucleic acid molecule ~~of claim 103,~~
encoding a polypeptide comprising:
(a) an amino acid sequence of SEQ ID NO:3; and
(b) an amino acid sequence of SEQ ID NO:5;
wherein ~~(a) consists of SEQ ID NO:3 and (b) consists of SEQ ID NO:5~~ (a) and (b) are
joined by an amino acid linker sequence of no more than 50 amino acids; and
wherein said polypeptide does not comprise a HER-2/Neu transmembrane domain
.
119. (Previously Presented) An isolated nucleic acid molecule encoding a polypeptide comprising SEQ ID NO:6.
120. (Previously Presented) An isolated nucleic acid molecule encoding a polypeptide comprising SEQ ID NO:7.
121. (Currently Amended) The nucleic acid molecule of claim 117 ~~93~~, wherein the polypeptide is secreted.
122. -123. (Canceled).
124. (Currently Amended) The nucleic acid molecule of claim 118 ~~103~~, wherein the polypeptide is secreted.

125. (Previously Presented) The composition of claim 109, comprising an oil-in-water emulsion.
126. (Previously Presented) The composition of claim 125, comprising tocopherol.
127. (Previously Presented) The composition of claim 111, wherein the immunostimulatory substance comprises 3D-MPL, QS21, or a combination of 3D-MPL and QS21.
128. (Previously Presented) The composition of claim 111, wherein the immunostimulatory substance comprises 3D-MPL and QS21 in an oil-in-water emulsion.
129. (Previously Presented) The composition of claim 128, comprising tocopherol.
130. (Previously Presented) The composition of claim 109, comprising a CpG-containing oligonucleotide.
131. (Canceled)
132. (Currently Amended) A viral vector comprising a nucleic acid molecule of claim 119 ~~131~~.
133. (Currently Amended) A composition comprising the nucleic acid molecule of claim 119 ~~131~~ and a physiologically acceptable carrier or diluent.
134. (Previously Presented) The composition of claim 133, wherein the composition is a vaccine.
135. (Previously Presented) The composition of claim 133, further comprising an immunostimulatory substance.
136. (Previously Presented) The composition of claim 133, wherein the nucleic acid molecule is a DNA molecule.
137. (Currently Amended) The nucleic acid molecule of claim 119 ~~131~~, wherein the polypeptide is secreted.
138. (Previously Presented) The composition of claim 133, comprising an oil-in-water emulsion.
139. (Previously Presented) The composition of claim 135, wherein the immunostimulatory substance comprises 3D-MPL, QS21, or a combination of 3D-MPL and QS21.

140. (Previously Presented) The composition of claim 133, further comprising a CpG-containing oligonucleotide.
141. (Canceled)
142. (Currently Amended) A viral vector comprising a nucleic acid molecule of claim 120 ~~141~~.
143. (Currently Amended) A composition comprising the nucleic acid molecule of claim 120 ~~141~~ and a physiologically acceptable carrier or diluent.
144. (Previously Presented)The composition of claim 143, wherein the composition is a vaccine.
145. (Previously Presented) The composition of claim 143, further comprising an immunostimulatory substance.
146. (Previously Presented) The composition of claim 143, wherein the nucleic acid molecule is a DNA molecule.
147. (Currently Amended) The nucleic acid molecule of claim 120 ~~141~~, wherein the polypeptide is secreted.
148. (Previously Presented) The composition of claim 143, comprising an oil-in-water emulsion.
149. (Previously Presented) The composition of claim 145, wherein the immunostimulatory substance comprises 3D-MPL, QS21, or a combination of 3D-MPL and QS21.
- 150.(Previously Presented) The composition of claim 143, further comprising a CpG-containing oligonucleotide.
151. (Currently Amended) A method of making a protein, the method comprising the steps of:
 - (a) introducing into a cell an expression vector comprising a nucleic acid molecule_ according to claim 119 or 120 ~~131 or claim 141~~;
 - (b) culturing the transfected cell; and
 - (c) purifying the expressed protein.
152. (Previously Presented) The method of claim 151, wherein the cell is a CHO cell.

- 153. (Previously Presented) The method of claim 151, wherein the cell is cultured in suspension, under serum-free conditions.
- 154. (Previously Presented) The method of claim 151, wherein the expressed protein is purified by a procedure comprising:
 - (a) anion exchange chromatography; and
 - (b) hydrophobic chromatography.
- 155. (Previously Presented) The composition of claim 99, comprising an oil-in-water emulsion.
- 156. (Previously Presented) The composition of claim 101, wherein the immunostimulatory substance comprises 3D-MPL, QS21, or a combination of 3D-MPL and QS21.
- 157. (Previously Presented) The composition of claim 99, further comprising a CpG-containing oligonucleotide.
- 158. (New) The composition of claim 155, comprising tocopherol.
- 159. (New) The composition of claim 101, wherein the immunostimulatory substance comprises 3D-MPL and QS21 in an oil-in-water emulsion.
- 160. (New) The composition of claim 159, comprising tocopherol.
- 161. (New) The composition of claim 138, comprising tocopherol.
- 162. (New) The composition of claim 139, wherein the immunostimulatory substance comprises 3D-MPL and QS21 in an oil-in-water emulsion.
- 163. (New) The composition of claim 162, comprising tocopherol.
- 164. (New) The composition of claim 148, comprising tocopherol.
- 165. (New) The composition of claim 149, wherein the immunostimulatory substance comprises 3D-MPL and QS21 in an oil-in-water emulsion.
- 166. (New) The composition of claim 165, comprising tocopherol.